← All trials
NCT06799013
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 10, 2025
- Primary completion
- Dec 31, 2026
- Completion date
- Jul 31, 2027
- First posted
- Jan 29, 2025
- Last posted
- Jul 28, 2025
- Enrollment
- 48
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- HDT BioLead sponsor
- HDT BioOfficial
- University of Texas, GalvestonCollaborator
- DF/Net ResearchCollaborator
- Technical Resources International, Inc. (TRI)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.